Logo
TheLifesciencesMag Magazine
2 months ago
FDA Approves Durvalumab for Advanced Endometrial Cancer Treatment

On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved AstraZeneca’s drug Durvalumab (IMFINZI®) for the treatment of primary advanced or recurrent endometrial cancer in patients with mismatch repair deficiency.

Endometrial cancer is recognized as the most common gynecologic cancer in the United States, with an estimated 66,200 new cases in 2023 alone.

Know More: https://thelifesciencesmag...

#FDAApproval #Durvalumab #EndometrialCancer #CancerTreatment #DrugApproval #MedicalBreakthrough #oncology

Nothing found!

Sorry, but we could not find anything in our database for your search query {{search_query}}. Please try again by typing other keywords.